Tejashree Chavan, Prajakta More
Abstract: The reason of this research was to develop a matrix-type transdermal therapeutic system containing drug Azelnidipine with different ratios of HPMC E5 and Eudragit RL100 by solvent evaporation technique using dibutyl phthalate incorporated as plasticizer. Azelnidipine, a long-acting dihydropyridine based calcium channel blocker, on oral administration, the drug undergoes extensive first pass metabolism. Delivery of Azelnidipine via transdermal route would minimize some of the deficiencies associated with the oral delivery and increase the bioavailability of the drug. Formulated transdermal films were physically evaluated with regard to thickness, weight variation, drug content, tensile strength, and folding endurance, percentage of moisture content, surface pH and water vapour transmission rate. The thickness ranged between 0.17 0.02 to 0.23 0.01 mm, Excellent uniformity of drug content among the various batches were seen, with all formulations and ranged from 96.3 0.2 % to 98.9 0.4 %. In-vitro drug release studies were performed by using Franz diffusion cell. Among all formulations, the maximum in vitro drug release (70.56 mg) over a period of 10 h was observed in the case of formulation no. F6, The cumulative % of drug permeation in 10 h was found to be in order of F6>F5>F4>F3>F2>F1.
Keywords: Azelnidipine, Eudragit RL100, Dibutyl phthalate, Transdermal patch